Resistant Arterial Hypertension Cohort Study

Completed

• Conditions: Essential Hypertension; Resistant Hypertension; Hypertension
• Interventions: Behavioral: motivational intervention for non-compliant individuals; Drug: standardized anti-hypertensive treatment; Drug: chlorthalidone

• Registration Number: NCT01083017
• Lead Sponsor: University Hospital, Geneva

Brief Summary

The purpose of this study is to investigate the epidemiology of resistant hypertension, evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the randomization of two doses of the diuretic used - chlorthalidone), study two interventions in the group of patients that is non-compliant, and study environmental and genetic variables of individuals with resistant hypertension in a family design.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-03-08
• Study First Submitted QC: 2010-03-08
• Study First Posted: 2010-03-09
• Study Start: 2011-04
• Primary Completion: 2017-05
• Study Completion: 2017-05
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-26
• Last Update Posted: 2018-10-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

• informed consent
• resistant hypertension at the moment of inclusion
• 18 years or more, both sexes are included
• women at reproductive age: consenting to use oral contraception

Read More

Exclusion Criteria

• patients mentally impaired or unable to give informed consent
• patients speaking only a foreign language other than French, German, or English
• patients living far away, making the study visits not practical

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
motivational invervention	motivational intervention for non-compliant individuals	motivational interview(s) vs. repeated calls vs. no particular intervention
standardized anti-hypertensive treatment	standardized anti-hypertensive treatment	-
chlorthalidone	chlorthalidone	-

Primary Outcome Measures

Name	Time	Method
blood pressure control	at 12 weeks after initiation of standard treatment

Secondary Outcome Measures

Name	Time	Method
cardiovascular morbidity and mortality	5 years	additional secondary: BP control at yearly follow-up

Trial Locations

Locations (3)

Geneva University Hospitals; 🇨🇭 Geneva, Switzerland

Kantonsspital Luzern; 🇨🇭 Luzern, Switzerland

Lausanne University Hospital, CHUV; 🇨🇭 Lausanne, Switzerland